DOCSLIB.ORG

Neurotech Clusters 2010

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neurotech Clusters 2010 MAPPING THE BUSINESS OF NEUROSCIENCE Neurotech Clusters 2010 LEADING REGIONS IN THE GLOBAL NEUROTECHNOLOGY INDUSTRY 2010 - 2020 About Neurotechnology Industry Organization The Neurotechnology Industry Organization (NIO) is a non-profit trade association representing companies involved in neuroscience (pharmaceuticals, biologics, cell-based therapeutics, medical devices and diagnostics), brain research institutes and advocacy groups across the United States and throughout the world. NIO was founded in 2006 and has attracted over 90 members in support of our mission to “give the brain a voice.” www.neurotechindustry.org About NeuroInsights As the neurotechnology market authority, NeuroInsights helps investors, industry and society understand and profit from the rapid growth in the market for treatments of brain and nervous system illnesses. NeuroInsights provides investment reports, market analysis, industry events and strategic advisory services to large corporations, venture funds, startups, governments and financial institutions. www.neuroinsights.com REPORT AUTHORS Zack Lynch, MA Founder, Executive Director Neurotechnology Industry Organization [email protected] Corey M. McCann, MD, PhD Analyst NeuroInsights [email protected] CONTRIBUTING AUTHOR CONTRIBUTING RESEARCHER Casey Crawford Lynch, MS Tim Rasmus, MD Managing Director Neuropathologist NeuroInsights, LLC Toronto General Hospital [email protected] [email protected] The information, data and estimates in this report have been obtained from sources believed to be reliable. Every reasonable effort has been made to verify their accuracy, but accuracy cannot be guaranteed. The information and opinions contained in this report are intended for informational purposes only and are not intended as investment advice. © Copyright 2009 NeuroInsights, LLC All Rights Reserved “The Neurotechnology Industry 2009 Report” and “Neurotech Insights” and “The Neurotech Index” are trademarks of NeuroInsights, LLC. Table of Contents Executive Summary 5 The Global Neurotech Economy 7 Role of Geographic Clusters in Neurotechnology 8 Neurotechnology Industry Taxonomy 9 Neuropharmaceuticals 11 Neurodevices 12 Neurodiagnostics 13 Neurotech Cluster Methodology 14 Neurotech Region Rankings 17 Top Tier Neurotech Clusters 19 San Francisco Bay Area, CA 19 Greater Boston, MA 20 Second Tier Neurotech Clusters 22 Greater New York, NY 22 London/Cambridge, United Kingdom 23 San Diego, CA 25 LA/Irvine, CA 27 Emerging Neurotech Clusters 29 Baltimore/Washington DC 29 Greater Philadelphia, PA 30 Minneapolis, MN 31 Nascent Neurotech Clusters 33 Montreal, Canada 33 Basel/Zurich, Switzerland 33 Tel Aviv, Israel 34 Seattle, WA 36 Stockholm, Sweden 37 Tokyo, Japan 38 Regions to Watch 40 Munich, Germany 40 Raleigh/Durham, NC 40 New Haven, CT 41 Chicago, IL 41 Shanghai, China 41 Cleveland, OH 42 3 Public Policy Recommendations 44 Report Data- Breakdown by Individual Metrics 45 Top Regions for Neurotech Companies 45 Top Regions for Private Neurotech Companies 46 Top Regions for Public Neurotech Companies 47 Top Regions for Neuropharmaceutical Companies 48 Top Regions for Neurodevice Companies 50 Top Regions for Neurodiagnostic Companies 52 Top Regions for Neurotech Risk Capital 53 Top Regions for Neurotech Infrastructure 55 Neurotech Education 56 Neurotech Healthcare 58 Neurotech Research 63 Neurotech in Big Pharma 66 Big Pharma Neurotechnology Rankings 67 Top Regions for Big Pharma Operations 68 Top Regions for Big Pharma Research 68 Company Summaries 69 Resources 90 About the Report Authors 91 4 Executive Summary Big economic payoffs will accrue to communities that successfully nurture the neurotechnology industry. The close collaboration of knowledge-intensive institutions, investors, businesses and workers fosters high-quality job creation, influx of investment capital and more robust economic growth. Neurotechnology represents the largest untapped medical market, and there are numerous opportunities available to regions that can leverage the dramatic growth of neurotech. Given the promise of new treatments, coupled with a patient population of over 2 billion people who suffer from a brain-related illness, neurotechnology has become a leading recipient of life science venture funding worldwide. Neurotechnology today is a truly a global industry with companies and cutting-edge research in the U.S., Europe, and Asia. As a nearly a $150-billion-a-year industry, neurotechnology, includes over 800 public and private organizations researching, developing and marketing pharmaceuticals, biologics, medical devices, as well as diagnostic and surgical equipment for the treatment of neurological, psychiatric illness and nervous system injuries.1 Given its size and growth trajectory, neurotechnology will play an important role in regional economic development in the coming decades. Brain-related illness generates more healthcare related costs and lost income than any other area of health: an estimated $2.0 trillion annually worldwide and $1.3 trillion annually in the U.S. Neurotechnology companies face fundamentally different investment requirements, research and development challenges, regulatory milestones and social drivers that set them apart from other life science and health care companies. For example, delivering therapeutics to the brain requires different techniques and technologies than is required for other organs such as the heart or kidney. In addition to the race for discovering more effective neurotherapeutics, there is another race underway: one that will determine where the primary geographic locations of the neurotech 1 The Neurotechnology Industry 2009 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System, Market Analysis and Strategic Investment Guide of the Global Neurological Disease and Psychiatric Illness Markets, published by NeuroInsights, LLC, May 2009. www.neuroinsights.com 5 industry reside and prosper. The economic outcomes of the formation and growth of these neurotechnology clusters will have long lasting implications on employment, infrastructure development, and regional competitiveness. The 21st century race to be a leading cluster for neurotech has many regional entries from the U.S. and around the world. Eight of the nine leading neurotech clusters are within the U.S. Many organizations exist with ties to the neurotechnology industry; in this report, over 1400 individual entities were catalogued, assigned geographies and classified according to NeuroInsights neurotechnology industry taxonomy (see page 9). Regions across the globe were evaluated according to the number of companies, access to risk capital and neurotechnology infrastructure. The two Top Tier Clusters are the Greater San Francisco Bay Area and the Greater Boston Area. These two regions represent the geographic centers of neurotechnology innovation, growth and development. The four Second Tier Clusters are New York/New Jersey, London/Cambridge, San Diego and Los Angeles/Irvine exhibit all of the necessary ingredients for significant innovation and growth in neurotechnology although they are less developed than the top tier clusters. The three Emerging Clusters are Baltimore, Philadelphia, and Minneapolis. Each posses significant resources and are poised for expansion in the years to come. Several other regions are also on the radar and while not yet clusters, will provide a significant proportion of the neurotechnology innovation in the years to come. These regions include our Nascent Clusters (Montreal, Basel/Zurich, Tel Aviv, Seattle, Stockholm, Tokyo) as well as our Regions to Watch (Munich, New Haven, Chicago, Shanghai, Raleigh/Durham, and Cleveland). Data gathered for the report also reveals several other interesting regional trends. New York/New Jersey is the leading region for public neurotechnology companies. Boston MA and Baltimore/DC are the leading regions for neurotechnology infrastructure based on strong graduate programs and hospital rankings in neuroscience related areas. The San Francisco Bay Area, Minneapolis, MN and Cleveland, OH are major centers for neurodevice development. 6 The Global Neurotech Economy Information provided from “The Neurotechnology Industry 2009 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System” published by NeuroInsights, San Francisco. Copyright Reminder: Cite the NeuroInsights report if any of below data are used in any way Market Overview The neurotechnology industry includes companies researching, developing and marketing pharmaceuticals, biologics, cell-based therapeutics and medical devices, as well as diagnostic and surgical equipment for the treatment of neurological diseases, nervous system ailments and psychiatric illnesses. The global economic burden of brain-related illnesses has eclipsed $2 trillion a year. The estimated US economic burden of brain-related illnesses exceeds $1.3 trillion. Neurotechnology addresses the largest unmet medical market: 2 billion people worldwide, including nearly 100 million in North America. Industry Overview Over 850 companies were involved in the neurotechnology industry in 2008. In 2008, neurotech companies generated revenues of $144.5 billion with 9.0% growth The neurotechnology industry has three sectors: – Neuropharmaceuticals with revenues of $121.6 billion and 9.3% annual growth – Neurodevices with revenues of $6.1 billion and 18.6% annual growth – Neurodiagnostics with revenues of $16.8 billion and 3.7% annual growth Venture Financing In 2008, venture capital
Load more

Recommended publications
  • Module 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods
    CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods Module 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods Copyright 2012 ViiV Healthcare and the GlaxoSmithKline group of companies. All rights reserved. Unauthorized copying or use of this information is prohibited. 1 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods TABLE OF CONTENTS PAGE ABBREVIATIONS ...........................................................................................................3 1. BACKGROUND AND OVERVIEW ...........................................................................4 1.1. Conclusions ..................................................................................................4 1.2. Formulation Development.............................................................................5 1.3. In Vitro Dissolution Data .............................................................................10 1.3.1. Comparative of 2 x 25 mg Clinical Tablets and 1 x 50 mg Clinical Tablets, Phase III Formulation.........................................10 1.3.2. Comparison of Phase III Clinical Image and Commercial Image Tablets..............................................................................13 1.4. Analytical Methods......................................................................................17 1.4.1. Validation.....................................................................................17 1.4.2. Summary of Within Study Quality
    [Show full text]
  • 2 FG9A Nationale Patente Brevets Nationaux Brevetti Nazionali
    15.4.2003 +pat+ 7 2 FG9A Daniela Montanari K Mehrzweckwerkzeug. Piazza Zanellato, 5 O Ejup Sulejmani Nationale Patente I-35129 Padova (IT) Klybeckstrasse 42 P Rottmann, Zimmermann + 4057 Basel (CH) Brevets nationaux Partner AG N Ejup Sulejmani Glattalstrasse 37 Gundeldingerrain 41 8052 Zürich (CH) 4059 Basel (CH) Brevetti nazionali P I A61N001/05 Abatron-Patentbüro AG A 693 200 Altstetterstrasse 224 B 02509/98 Postfach 2.3 FG3A C 18.12.1998 8048 Zürich (CH) F 10.01.1998 DE 198 00 697.7 I B 23 B 051/08 Z B 23 B 027/16 Ohne Vorprüfung erteilte K Einzel-Elektrodensonde, A 693 203 Patente insbesondere für implantierbare I Z Defibrillatoren. B 24 B 003/48 C 23 F 001/06 A Brevets délivrés sans O Biotronik Mess- und Therapiegeräte 693 210 examen préalable GmbH & Co. Ingenieurbüro Berlin I B 24 B 003/54 Z C 23 F 001/06 Woermannkehre 1 A 693 210 Brevetti rilasciati senza D-12359 Berlin (DE) esame preventivo N Dr. Tran Thong I B 24 B 055/03 Z B 01 D 037/00 12491 NW Woodland Court A 693 201 Portland, Oregon 97229 (US) I B 27 G 013/00 Z B 23 B 027/16 P I A 01 C 003/02 Z B 65 D 090/42 Patentanwälte Schaad, Balass, A 693 203 A 693 207 Menzl & Partner AG Dufourstrasse 101 I B60N002/48 I A47F007/10 8034 Zürich (CH) A 693 204 A 693 197 B 01795/98 I B 01793/98 B01D037/00, B 24 B 055/03 C 02.09.1998 A C 02.09.1998 693 201 F 05.09.1997 DE 297 16 525.9 B K Halter für die Verkaufspräsentation 00941/98 03.11.1997 DE 297 20 023.2 C von textilen Artikeln, insbesondere 24.04.1998 K Kopfstütze und Polster- oder F Strümpfen und Gestell mit solchen 25.04.1997 JP 9-108611 Kissenelement für Kopfstütze.
    [Show full text]
  • Pat 0.Vp:Corelventura
    Lietuvos Respublikos valstybinio patentø biuro oficialiame biuletenyje skelbiami iðradimai, dizainas, prekiø þenklai, registruoti Lietuvos Respublikos registruose pagal 2000 m. spalio 10 d. Lietuvos Respublikos prekiø þenklø ástatymà Nr. VIII-1981, 1994 m. sausio 18 d. Lietuvos Respublikos patentø ástatymà Nr. I-372, 2002 m. lapkrièio 7 d. Lietuvos Respublikos dizaino ástatymà Nr. IX–1181, Europos patentinës paraiðkos bei patentai, iðplësti Lietuvos Respublikoje 1994 m. sausio 25 d. Lietuvos Respublikos Vyriausybës ir Europos Patentø organizacijos (EPO) susitarimu dël Europos patentø galiojimo iðplëtimo, bei Europos patentinës paraiðkos, paduotos pagal Europos patentø konvencijà (EPK), kurioms suteikta laikina apsauga Lietuvos Respublikoje ir Europos patentai, ásigaliojæ Lietuvos Respublikoje pagal EPK. Iðradimø, dizaino, prekiø þenklø bei Europos patentiniø paraiðkø bei patentø paskelbimo ðiame oficialaus biuletenio numeryje data - 2006 m. birþelio 26 d. The Official Gazette of the State Patent Bureau of the Republic of Lithuania contains recordings in the Registers of Patents, Designs, Trademarks of the Respublic of Lithuania under the Law on Trademarks of the Republic of Lithuania No. VIII-1981 of October 10, 2000, the Patent Law of the Republic of Lithuania No. I-372 of January 18, 1994, the Design Law of the Republic of Lithuania No. IX–1181 of November 7, 2002, data on European Patent Applications and Patents extended to Republic of Lithuania under the Agreement on the extension of European Patents between the Government of the Republic of Lithuania and the European Patent Organization (EPO) of January 25, 1994, and European Patent Applications filed under European Patent Convention (EPC), that have provisional protection in Republic of Lithuania, and Europian Patents granted in Republic of Lithuania according to EPC.
    [Show full text]
  • 053 Bactosomes References
    References Papers Evaluation of Escherichia coli Membrane Preparations of Canine CYP1A1, CYP2B11, 2C21, 2C41, 2D15, 3A12 and 3A26 with Coexpressed Canine Cytochrome P450 Reductase. C. W. Locuson, B. T. Ethell, M. W. Voice, D. Lee & K. L. Feenstra (Pfizer Animal Health, Veterinary Medicine Research & Development, Metabolism & Safety, Kalamazoo, Michigan, USA; Pfizer Global Research & Development Pharmacokinetics, Dynamics & Metabolism, Sandwich, Kent, UK; Cypex Ltd, Dundee, UK; Advantagen Ltd, Dundee, UK) Drug Metabolism & Disposition (2009), Vol 37 (3), p457 – 461, Pharmacology and Metabolism of Renzapride. N. L. Meyers & R. I. Hickling (Alizyme Therapeutics Ltd, Cambridge, UK) Drugs R D (2008), Vol 9 (1), p37 - 63 Prediction of the Metabolic Interaction of Nateglinide with Other Drugs Based on in vitro Studies. T. Takanohashi, T. Koizumi, R. Mihara & *K. Okudaira (Pharmaceutical Company, Ajinomoto Co., Inc., Kawasaki, Japan; *Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan) Drug Metabolism & Pharmacokinetics (2007) Vol 22 (6), p409 - 418 Silybin is Metabolized by Cytochrome P450 2C8 in vitro. P. Jan čová, E. Anzenbacherová, B. Papoušková, K. Lemr, P. Lužná, A. Veinlichová, P. Anzenbacher & V. Šimánek (Palacky University at Olomouc, Olomouc, Czech Republic) Drug Metabolism & Disposition (2007), Vol 35 (11), p2035 - 2039 Sulfamethoxazole and its Metabolite Nitroso Sulfamethoxasole Stimulate Dendritic Cell Costimulatory Signaling. J. p. Sanderson, D. J. Naisbitt, J. Farrell, C. A. Ashby, M. J. Tucker, M. J. Rieder,
    [Show full text]
  • 158S ASMS Directory of Members DAVID AASERUD the Lubrizol
    158S ASMS Directory of Members DAVID AASERUD ANDREW ACHEAMPONG EMILY ADARAYAN The Lubrizol Corporation Allergan Pharmaceuticals Merck & Co. 29400 Lakeland Blvd. 2525 Dupont Drive, RD-2B PO Box 4 Wickliffe OH 44092 Irvine CA 92612 wp75-200 Tel: 440 347 4776 Tel: 714 246 4950 West Point PA 19486-0004 [email protected] [email protected] Tel: 215 652 3045 [email protected] CHRISTY ABBAS-HAWKS SUZANNE ACKLOO Colorado School of Mines MDS Sciex TOM ADDISON Coolbaugh Hall 71 Four Valley Drive Covance-11 Golden CO 80401 Concord ON L4K 4V8 CANADA 6002/11 Tel: 303 273 3579 Tel: 905 660 9005 3301 Kinsman Boulevard [email protected] [email protected] Madison WI 53704-2523 Tel: 608 242 2639 SUSAN ABBATIELLO EUREKA ACOLATSE [email protected] University of Florida 7237 Causeway Drive #3B Department of Chemistry Indianapolis IN 46214 TERRI ADDONA PO Box 117200 Tel: 317 433 4016 Millennium Pharmaceuticals Gainesville FL 32611 [email protected] 45 Sidney Street Tel: 352 392 0536 Cambridge MA 02139 [email protected] CHRIS ADAMS Tel: 617 679 7481 Uppsala University [email protected] LARRY ABBEY Biological & Medical Mass Spec Waters Corporation Box 583, BMC ANTHONY ADEUYA 4026 Oak Crest Drive Uppsala, SE-751 23 SWEDEN Purdue University Tucker GA 30084 Tel: 46 18 471 5729 PO Box 5323 Tel: 770 414 5089 [email protected] Lafayette IN 47903 [email protected] Tel: 765 420 7773 NIGEL G. ADAMS [email protected] FRANK S. ABBOTT University of Georgia Faculty of Pharmaceutical Science Department of Chemistry ARIE ADMON University of British Columbia Cedar Street Technion - Israel Institute of Tech 2146 East Mall Athens GA 30602 Department of Biology Vancouver BC V6T 1Z3 CANADA Tel: 706 542 3722 Haifa 32000 32000 ISRAEL Tel: 604 822 2566 [email protected] Tel: 972 48293407 [email protected] [email protected] ROBERT A.
    [Show full text]
  • Synthesis, Antimalarial Activity, and Preclinical Pharmacology of a Novel Series of 4′-Fluoro and 4′-Chloro Analogues of Amodiaquine
    1828 J. Med. Chem. 2009, 52, 1828–1844 Synthesis, Antimalarial Activity, and Preclinical Pharmacology of a Novel Series of 4′-Fluoro and 4′-Chloro Analogues of Amodiaquine. Identification of a Suitable “Back-Up” Compound for N-tert-Butyl Isoquine Paul M. O’Neill,*,†,‡ Alison E. Shone,‡ Deborah Stanford,† Gemma Nixon,† Eghbaleh Asadollahy,† B. Kevin Park,‡ James L. Maggs,‡ Phil Roberts,‡ Paul A. Stocks,† Giancarlo Biagini,§ Patrick G. Bray,§ Jill Davies,§ Neil Berry,† Charlotte Hall,§ Karen Rimmer,§ Peter A. Winstanley,‡ Stephen Hindley,† Ramesh B. Bambal,| Charles B. Davis,| Martin Bates,⊥ Stephanie L. Gresham,# Richard A. Brigandi,∇ Federico M. Gomez-de-las-Heras,O Domingo V. Gargallo,O Silvia Parapini,¶ Livia Vivas,[ Hollie Lander,[ Donatella Taramelli,¶ and Stephen A. Ward§ Department of Chemistry, UniVersity of LiVerpool, LiVerpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, UniVersity of LiVerpool, LiVerpool L69 3GE, U.K., LiVerpool School of Tropical Medicine, Pembroke Place, LiVerpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug DiscoVery, 1250 South CollegeVille Road, CollegeVille, PennsylVania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood Road, SteVenage, Hertfordshire SG1 2NY, U.K., Safety Assessment, GlaxoSmithKline, The Frythe, Welwyn, Hertfordshire AL6 9AR, U.K., DiscoVery Medicine Infectious Diseases CEDD, DDW DPU, GlaxoSmithKline, Upper ProVidence, PennsylVania, GlaxoSmithKline, S.A., Parque Tecnolo´gico de Madrid, SeVero Ochoa, 2, 28760 Tres Cantos, Madrid, Spain, Dipartimento di Sanita` Pubblica, Microbiologia, Virologia, UniVersita` degli Studi di Milano, Via Pascal, 36, 20133 Milan, Italy, and Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, U.K.
    [Show full text]
  • ASMS Directory of Members
    ASMS Directory of Members DAVID AASERUD FRED P ABRAMSON JEANETTE ADAMS DEPARTMENT OF CHEMISTRY DEPARTMENT OF PHARMACOLOGY DEPARTMENT OF CHEMISTRY BOX 342, BAKER LAB GEORGE WASHINGTON UNIVERSITY EMORY UNIVERSITY CORNELL UNIVERSITY 2300 EYE STREET NORTHWEST ATLANTA, GA30322 ITHACA, NY 14853 WASHINGTON , DC 20037 Phone: 404 7276522 Phone: 6072553731 Phone: 2029942946 Fax: 404 7276586 Fax: 607255-7880 Fax: 202 994 2870 [email protected] LARRY ABBEY ANDREW ACHEAMPONG NATHAN ADAMS TRIANGLE LABS OF ATLANTA, INC ALLERGAN PHARMACEUTICALS DEPARTMENT OF CHEMISTRY \703 WEBB DR, SUITE C 2525 DUPONT DRIVE UNIVERSITY OF NORTHERN lOWA NORCROSS , GA 30093 IRVINE, CA 92715 CEDAR FALLS, IA 50614-0423 Phone: 4044466393 Phone: 714 724 4950 Phone: 3192732435 Fax: 4044466392 Fax: 714 724 5850 [email protected] FRANK S ABBOTT BRADLEY L ACKERMANN NIGEL G ADAMS FACULTY OF PHARMACEUTICAL SCI MARION MERRELL DOW, INC DEPARTMENT OF CHEMISTRY UNIVERSITY OF BRITISH COLUMBIA 2110 E GALBRAITH ROAD UNIVERSITY OF GEORGIA 2\46 EAST MALL BLDG. 26-1 ATHENS, GA 30602 VANCOUVER, BC, V6T \23 CINCINNATI, OH 45215-6300 Phone : 4045423722 CANADA Phone: 513 948 6081 Fax: 4045429454 Phone: 604822 2566 Fax: 513 9487360 [email protected] Fax: 6048223035 [email protected]!vID.COM ROBERT A ADAMS MAGED ABDELRAHIM MICHAELRACKERMANN ARLSINC. WALTER REED ARMY MEDICAL CTR FISONS INSTRUMENTS 3480 TANBARK CT. NE DEPT OF CLINICAL INVESTIGATION 55 CHERRY HILL DRIVE ATLANTA, GA30319 WASHINGTON, DC 20307 BEVERLY, MA 01915 Phone: 4042554817 Phone: 202 782 7612 Phone: 508524
    [Show full text]
  • 2 FG9A Nationale Patente Brevets Nationaux Brevetti Nazionali
    30.6.2004 +pat+12 2 FG9A Klaus Berghaus mehrerer Gegenstände auf einem Lehmgrubenweg 5 Substrat und Verfahren zum Betrieb Nationale Patente 89155 Erbach (DE) dieser Vorrichtung P Braun & Partner Patent-, Marken-, O Delsys Pharmaceutical Corporation Brevets nationaux Rechtsanwälte 5 Vaughn Drive, Suite 305 Reussstrasse 22 Princeton, NJ 08540 (US) Brevetti nazionali CH-4054 Basel (CH) N Hoi Cheong Steve Sun 3-09 Pheasant Hollow Drive I A 61 K 031/196 Z C 07 C 229/50 Plainsboro NJ 08536 (CH) A 694 053 Christina Knoedler 2.3 FG3A I A 61 K 035/20 Z A 61 K 035/78 118 North Park Road A 694 035 Newtown PA 18940 (US) P Micheli & Cie ingénieurs-conseils Ohne Vorprüfung erteilte I Patente A61K035/78, A 61 K 035/20, 122, rue de Genève A61K009/127, B 01 D 015/02 Case postale 61 A Brevets délivrés sans 694 035 1226 Thônex (Genève) (CH) B 02131/99 examen préalable C 23.11.1999 I B 01 L 009/00 Z G 01 N 015/05 A Brevetti rilasciati senza K Verfahren zur Isolierung von 694 062 lipophilen Wirkstoffen aus I B05B001/34 esame preventivo pflanzlichem und/oder tierischem A 694 039 Material. B 00909/00 O Dr. Ingrid Weis C 10.05.2000 I A42B001/04 Bergmattenweg 81 K Verfahren und Vorrichtung zur A 694 032 4148 Pfeffingen (CH) Erzeugung eines laminaren oder B 02216/02 N Dr. Ingrid Weis quasi laminaren kohärenten C 27.12.2002 Bergmattenweg 81 Flüssigkeitsstrahls. K Kopfbedeckung, insbesondere Beret. 4148 Pfeffingen (CH) O Prof. Dr.
    [Show full text]
  • Hertfordshire London Arc Final Report March 2009
    Broxbourne, Dacorum, Hertsmere, St. Albans, Three Rivers, Watford and Welwyn Hatfield Councils HERTFORDSHIRE LONDON ARC JOBS GROWTH AND EMPLOYMENT LAND Final Report March 2009 ROGER TYM & PARTNERS Fairfax House 15 Fulwood Place London WC1V 6HU t (020) 7831 2711 f (020) 7831 7653 e [email protected] w www.tymconsult.com This document is formatted for double-sided printing. P1850 CONTENTS 1 INTRODUCTION .......................................................................................................... 1 2 POLICY CONTEXT ...................................................................................................... 3 Introduction ..................................................................................................................... 3 National Policy ................................................................................................................ 3 Regional Policy ............................................................................................................... 5 Legal Policy .................................................................................................................. 11 3 THE ECONOMY ........................................................................................................ 21 Competitiveness and Well-Being .................................................................................. 21 Employment Change .................................................................................................... 22 4 THE INDUSTRIAL/WAREHOUSING MARKET
    [Show full text]
  • Built to Resist an Assessment of the Special Operations Executive’S Infrastructure in the United Kingdom During the Second World War, 1940-1946
    Built to Resist An Assessment of the Special Operations Executive’s Infrastructure in the United Kingdom during the Second World War, 1940-1946 Derwin Gregory MA (cantab) MA PCIfA VOLUME I A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy in the School of History UNIVERSITY OF EAST ANGLIA 2015 This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with the author and that use of any information derived there from must be in accordance with current UK Copyright Law. In addition, any quotation or extract must include full attribution. Declaration I hereby declare that this thesis has not been and will not be submitted in whole or in part to any other University for the award of any other degree. Derwin Gregory i Abstract During the Second World War, the British Government established the Special Operations Executive (SOE) for the purpose of coordinating ‘all action, by way of subversion and sabotage, against the enemy overseas’. Although the overseas operations of this branch of the British Secret Services are relatively well known, no previous study has assessed the organisation’s UK based infrastructure. This thesis represents the first time the entire UK property portfolio of a clandestine government agency has been assessed. By addressing this gap in our knowledge, this thesis has increased the number of identified properties operated by SOE by 30%. This was achieved by undertaking a desk based assessment which combined pre-existing historical and archaeological methodologies.
    [Show full text]
  • Effect of Repeated Intrathecal Thyrotrophin-Releasing Hormone (Trh) Or Trh Analogue Administration on Spinal Motoneurones
    565P EFFECT OF REPEATED INTRATHECAL THYROTROPHIN-RELEASING HORMONE (TRH) OR TRH ANALOGUE ADMINISTRATION ON SPINAL MOTONEURONES K.C.F. Fone*, J.V. Johnson, G.W. Bennett & C.A. Marsden, Department of Physiology and Pharmacology, Medical School, Queen's Medical Centre, Nottingham NG7 2UH. Electronmicroscopic evidence shows that thyrotrophin-releasing hormone-like immunoreactivity (TRH-LI) is located in boutons making synaptic contact with spinal motoneurones (Ulfhake et al., 1987) but the role of TRH in regulating normal spinal motor output is unknown. TRH may exert a trophic-like action on motoneurones as suggested by the elevation of choline acetyltransferase (ChAT) activity in cultured motoneurones exposed to TRH (Schmidt-Achert et al., 1984). The present study compared the effect of repeated intrathecal administration of TRH (pGln-His-ProNH2), the C-terminal modified TRH analogue RX 77368 (pGln-His- 3,3'-dimethyl-ProNH2) and N-terminal modified CG 3509 (orotyl-His-ProNH2) on ChAT activity and calcitonin-gene related peptide (CGRP)-LI in the rat ventral horn, which are both principally located in motoneurones in this region, as biochemical markers for motoneurones. In addition plasma thyroid stimulating hormone (TSH) and free thyroxine (T4) levels were measured to assess the neuroendocrine effects of the TRH peptides. Male Wistar rats (270-320g) were anaesthetised with sodium methohexitone (60mg/kg i.p.) to permit implantation of an intrathecal cannula (Fone et al., 1987). After a seven day recovery period rats (n=8 in each group) received nine successive intrathecal injections of either saline (10p1 + 15pl wash-in), TRH (20pg), CG 3509 (2pg) or RX 77368 (2pg), doses which were equipotent at producing wet-dog shakes when given intrathecally, twice daily (between 08.30-09.30 and 17.30-18.30h) for five days.
    [Show full text]
  • Norsk Patenttidende Nr 11/05
    . nr 11/05 - 2005.03.14 årgang 95 ISSN 1503-4933 . innholdsfortegnelse 2005.03.14 - nr 11/05 Innholdsfortegnelse Innholdsfortegnelse.............................................................................................2 Nye patentsøknader............................................................................................3 Allment tilgjengelige patentsøknader (A)...........................................................28 Meddelte patenter B1 ......................................................................................109 Oppreisning.....................................................................................................122 Trukket, Avslåtte og henlagte søknader som er allment tilgjengelige .............123 Nye søknader om supplerende beskyttelsessertifikater (SPC) .......................124 Utpekning og endring av fullmektig og fullmaktsforhold ..................................125 Navneendringer...............................................................................................126 Rettelse ...........................................................................................................127 2 nye patentsøknader 2005.03.14 - nr 11/05 Nye patentsøknader Fortegnelse etter patentforskriftens § 8 over innkomne patentsøknader. Patentsøknad nr 20051071-20051221 Følgende nr i serien har ikke innhold 20051114, 20051121, 20051131, 20051160, 20051188, 20051210 (51) Klasse : A01K (51) Klasse : A22C (21) Søknadsnr : 20051113 (21) Søknadsnr : 20051173 (22) Inng.dag : 2005.03.02 (22) Inng.dag
    [Show full text]